Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

09 oct. 2019 16h30 HE | Source: Cue Biopharma

Cue Biopharma Announces Changes to its Board of Directors

CAMBRIDGE, Mass., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE) a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively...
09 oct. 2019 08h00 HE | Source: Cue Biopharma

Cue Biopharma to Present at Upcoming October 2019 Scientific Conferences

CAMBRIDGE, Mass., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively...
07 oct. 2019 16h30 HE | Source: Cue Biopharma

Cue Biopharma Promotes Dr. Anish Suri to President and CSO

CAMBRIDGE, Mass., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE) a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively...
02 oct. 2019 08h00 HE | Source: Cue Biopharma

Cue Biopharma to Present Corporate Overview and Update on Clinical Development Progress for CUE-101 at the Cantor 2019 Global Healthcare Conference

CAMBRIDGE, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively...
30 sept. 2019 08h00 HE | Source: Cue Biopharma

Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 for HPV16-driven Head and Neck Squamous Cell Carcinoma

CAMBRIDGE, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively...